ReviewNature reviews. Neuroscience2024
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box.
Review in Nature reviews. Neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Neuroimaging Insights into the Public Health Burden of Neuropsychiatric Disorders: A Systematic Review of Electroencephalography-Based Cognitive Biomarkers.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Cortical thickness changes precede high levels of amyloid by at least 7 years.Nature neuroscience · 2026Article
- CLEAR: an auditable foundation model for radiology grounded in clinical concepts.Nature biomedical engineering · 2026Article
- Genetic Associations with Temporal Modeling of Alzheimer's Disease Progression Supports a Novel Paradigm for Disease Risk.medRxiv : the preprint server for health sciences · 2026Article
- Forecasting Alzheimer's disease progression via identity-preserved denoising diffusion generative adversarial network.NPJ digital medicine · 2026Article
- Estimating the time course of biomarker changes in Alzheimer's disease.Brain : a journal of neurology · 2026Article
- Prediction of alzheimer's disease time to dementia onset using cross-sectional data from spatiotemporal biomarker progression patterns.European journal of nuclear medicine and molecular imaging · 2026Article
- Age-related determinants of geriatric depression: an analysis of theory-driven and data-driven approaches.BMC health services research · 2026Article
- Decomposing heterogeneity in disease progression speeds and pathways.NPJ digital medicine · 2026Article
- Disentangling global atrophy burden from local structural patterns reveals clinically relevant heterogeneity in mild cognitive impairment.Research square · 2026Article
- Can Psychiatric Genetics Advance Without Incorporating a Life Course Perspective?Biological psychiatry · 2026Review
- Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer's disease.Research square · 2026Article
- Time and person sensitive foundation model for disease prediction and risk stratification.NPJ digital medicine · 2026Article
- TeroACT: A terpenoid bioactivity landscape and discovery platform.Acta pharmaceutica Sinica. B · 2026Article
- The Axon as a Self-Modifying Computational System: Autonomous Inference, Adaptive Propagation, and AI-Enabled Mechanistic Insight.International journal of molecular sciences · 2026Review
- Brain-age in ultra-low-field MRI: How well does it work?Imaging neuroscience (Cambridge, Mass.) · 2026Article
- LNODE: Uncovering the Latent Dynamics ofMedical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2026Article
- Cognitive trajectories of older adults before and after the COVID-19 pandemic: socioeconomic and psychological disparities in the Lc65+ cohort.Innovation in aging · 2026Article
- Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease.Brain communications · 2026Article
- Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment.EBioMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Data-driven disease progression models are an emerging set of computational tools that reconstruct disease timelines for long-term chronic diseases, providing unique insights into disease processes and their underlying mechanisms. Such methods combine a priori human knowledge and assumptions with large-scale data processing and parameter estimation to infer long-term disease trajectories from short-term data. In contrast to 'black box' machine learning tools, data-driven disease progression models typically require fewer data and are inherently interpretable, thereby aiding disease understanding in addition to enabling classification, prediction and stratification. In this Review, we place the current landscape of data-driven disease progression models in a general framework and discuss their enhanced utility for constructing a disease timeline compared with wider machine learning tools that construct static disease profiles. We review the insights they have enabled across multiple neurodegenerative diseases, notably Alzheimer disease, for applications such as determining temporal trajectories of disease biomarkers, testing hypotheses about disease mechanisms and uncovering disease subtypes. We outline key areas for technological development and translation to a broader range of neuroscience and non-neuroscience applications. Finally, we discuss potential pathways and barriers to integrating disease progression models into clinical practice and trial settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.